Chen, X., Gao, M., An, S., Zhao, L., Han, W., Wan, W., Chen, J., Ma, S., Cai, W., Cao, Y., Ding, D., Yang, Y. Y., Cheng, L., & Zheng, Y. (2022). Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine: Nanotechnology, Biology, and Medicine, 45, Article 102591. https://doi.org/10.1016/j.nano.2022.102591
Chen, Xingye ; Gao, Mengqian ; An, Shan et al. / Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2022 ; Vol. 45.
@article{cd162cbeeef342bbbc30b666f7212554,
title = "Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels",
abstract = "The efficacy of Adoptive Cell Therapy (ACT) for solid tumor is still mediocre. This is mainly because tumor cells can hijack ACT T cells' immune checkpoint pathways to exert immunosuppression in the tumor microenvironment. Immune Checkpoint Inhibitors such as anti-PD-1 (aPD1) can counter the immunosuppression, but the synergizing effects of aPD1 to ACT was still not satisfactory. Here we demonstrate an approach to safely anchor aPD1-formed nanogels onto T cell surface via bio-orthogonal click chemistry before adoptive transfer. The spatial-temporal co-existence of aPD1 with ACT T cells and the responsive drug release significantly improved the treatment outcome of ACT in murine solid tumor model. The average tumor weight of the group treated by cell-surface anchored aPD1 was only 18 % of the group treated by equivalent dose of free aPD1 and T cells. The technology can be broadly applicable in ACTs employing natural or Chimeric Antigen Receptor (CAR) T cells.",
keywords = "Adoptive cell therapy, CAR-T therapy, Cell backpack, Immune checkpoint blockade, Tumor microenvironment",
author = "Xingye Chen and Mengqian Gao and Shan An and Lei Zhao and Wenqing Han and Wenjun Wan and Jin Chen and Siqi Ma and Wenhua Cai and Yanni Cao and Dawei Ding and Yang, {Yi Yan} and Lifang Cheng and Yiran Zheng",
note = "Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = sep,
doi = "10.1016/j.nano.2022.102591",
language = "English",
volume = "45",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
}
Chen, X, Gao, M, An, S, Zhao, L, Han, W, Wan, W, Chen, J, Ma, S, Cai, W, Cao, Y, Ding, D, Yang, YY, Cheng, L & Zheng, Y 2022, 'Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 45, 102591. https://doi.org/10.1016/j.nano.2022.102591
Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. / Chen, Xingye; Gao, Mengqian; An, Shan et al.
In:
Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 45, 102591, 09.2022.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels
AU - Chen, Xingye
AU - Gao, Mengqian
AU - An, Shan
AU - Zhao, Lei
AU - Han, Wenqing
AU - Wan, Wenjun
AU - Chen, Jin
AU - Ma, Siqi
AU - Cai, Wenhua
AU - Cao, Yanni
AU - Ding, Dawei
AU - Yang, Yi Yan
AU - Cheng, Lifang
AU - Zheng, Yiran
N1 - Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - The efficacy of Adoptive Cell Therapy (ACT) for solid tumor is still mediocre. This is mainly because tumor cells can hijack ACT T cells' immune checkpoint pathways to exert immunosuppression in the tumor microenvironment. Immune Checkpoint Inhibitors such as anti-PD-1 (aPD1) can counter the immunosuppression, but the synergizing effects of aPD1 to ACT was still not satisfactory. Here we demonstrate an approach to safely anchor aPD1-formed nanogels onto T cell surface via bio-orthogonal click chemistry before adoptive transfer. The spatial-temporal co-existence of aPD1 with ACT T cells and the responsive drug release significantly improved the treatment outcome of ACT in murine solid tumor model. The average tumor weight of the group treated by cell-surface anchored aPD1 was only 18 % of the group treated by equivalent dose of free aPD1 and T cells. The technology can be broadly applicable in ACTs employing natural or Chimeric Antigen Receptor (CAR) T cells.
AB - The efficacy of Adoptive Cell Therapy (ACT) for solid tumor is still mediocre. This is mainly because tumor cells can hijack ACT T cells' immune checkpoint pathways to exert immunosuppression in the tumor microenvironment. Immune Checkpoint Inhibitors such as anti-PD-1 (aPD1) can counter the immunosuppression, but the synergizing effects of aPD1 to ACT was still not satisfactory. Here we demonstrate an approach to safely anchor aPD1-formed nanogels onto T cell surface via bio-orthogonal click chemistry before adoptive transfer. The spatial-temporal co-existence of aPD1 with ACT T cells and the responsive drug release significantly improved the treatment outcome of ACT in murine solid tumor model. The average tumor weight of the group treated by cell-surface anchored aPD1 was only 18 % of the group treated by equivalent dose of free aPD1 and T cells. The technology can be broadly applicable in ACTs employing natural or Chimeric Antigen Receptor (CAR) T cells.
KW - Adoptive cell therapy
KW - CAR-T therapy
KW - Cell backpack
KW - Immune checkpoint blockade
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85135350751&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2022.102591
DO - 10.1016/j.nano.2022.102591
M3 - Article
C2 - 35907618
AN - SCOPUS:85135350751
SN - 1549-9634
VL - 45
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
M1 - 102591
ER -
Chen X, Gao M, An S, Zhao L, Han W, Wan W et al. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine: Nanotechnology, Biology, and Medicine. 2022 Sept;45:102591. doi: 10.1016/j.nano.2022.102591
